Species |
Human |
Protein Construction |
B7-H2/ICOSLG (Asp19-Ser258) Accession # O75144-1 |
hFc |
N-term |
C-term |
|
Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
Endotoxin Level |
Less than 1EU per μg by the LAL method. |
Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Human ICOS, His Tag at 0.5μg/ml (100μl/Well) on the plate can bind B7-H2/ICOSLG hFc Chimera, Human. Test result was comparable to standard batch. |
Expression System |
HEK293 |
Theoretical Molecular Weight |
53.4 kDa |
Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 75-100 kDa based on Bis-Tris PAGE result. |
Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
Target Background |
B7-H2, also known as B7-related protein (B7RP1), ICOS Ligand, and CD275, is an approximately 60 kDa transmembrane glycoprotein in the B7 family of immune regulatory molecules. B7-H2 is a ligand for the T-cell-specific cell surface receptor ICOS. Acts as a costimulatory signal for T-cell proliferation and cytokine secretion; induces also B-cell proliferation and differentiation into plasma cells. |
Synonyms |
CD275; B7H2; B7-H2; B7RP-1; GL50; ICOSL; ICOS-L; ICOSLG; B7RP1; LICOS; ICOS ligand; B7-H2B7-related protein 1; B7RP-1; B7RP1B7-like protein Gl50 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.